About Eton Pharmaceuticals, Inc.
https://www.etonpharma.comEton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases.
CEO
Sean E. Brynjelsen
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 63
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
OPALEYE MANAGEMENT INC.
Shares:2.86M
Value:$44.82M
ECOR1 CAPITAL, LLC
Shares:2.03M
Value:$31.82M
BLACKROCK, INC.
Shares:1.7M
Value:$26.71M
Summary
Showing Top 3 of 106
About Eton Pharmaceuticals, Inc.
https://www.etonpharma.comEton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $22.46M ▲ | $9.22M ▼ | $-1.93M ▲ | -8.58% ▲ | $-0.07 ▲ | $266K ▲ |
| Q2-2025 | $18.93M ▲ | $13.4M ▲ | $-2.58M ▼ | -13.66% ▼ | $-0.1 ▼ | $-470K ▼ |
| Q1-2025 | $17.28M ▲ | $10.33M ▲ | $-1.57M ▼ | -9.1% ▼ | $-0.06 ▼ | $543K ▼ |
| Q4-2024 | $11.65M ▲ | $5.85M ▲ | $-598K ▼ | -5.13% ▼ | $-0.02 ▼ | $984K ▲ |
| Q3-2024 | $10.32M | $5.79M | $627K | 6.07% | $0.02 | $787K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $37.12M ▲ | $104.51M ▲ | $81.38M ▲ | $23.13M ▼ |
| Q2-2025 | $25.38M ▲ | $101.68M ▲ | $77.72M ▲ | $23.96M ▼ |
| Q1-2025 | $17.42M ▲ | $84.03M ▲ | $59.58M ▲ | $24.45M ▲ |
| Q4-2024 | $14.94M ▼ | $76.12M ▲ | $51.7M ▲ | $24.43M ▲ |
| Q3-2024 | $20.26M | $35.84M | $19.86M | $15.98M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.93M ▲ | $12.03M ▲ | $-284K ▼ | $0 | $11.74M ▲ | $11.74M ▲ |
| Q2-2025 | $-2.58M ▼ | $7.96M ▲ | $0 | $0 ▼ | $7.96M ▲ | $7.96M ▲ |
| Q1-2025 | $-1.57M ▼ | $2.09M ▲ | $0 ▲ | $394K ▼ | $2.48M ▲ | $2.09M ▲ |
| Q4-2024 | $-598K ▼ | $-765K ▼ | $-38.13M ▼ | $33.57M ▲ | $-5.33M ▼ | $-777K ▼ |
| Q3-2024 | $627K | $2.95M | $0 | $-385K | $2.57M | $2.95M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 License | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product Sales and Royalties | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $10.00M ▼ |
CEO
Sean E. Brynjelsen
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 63
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
OPALEYE MANAGEMENT INC.
Shares:2.86M
Value:$44.82M
ECOR1 CAPITAL, LLC
Shares:2.03M
Value:$31.82M
BLACKROCK, INC.
Shares:1.7M
Value:$26.71M
Summary
Showing Top 3 of 106